Katie Morris

Dr. Katie Morris

Physics, University of York, York, UK
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
MCMinee L. Choi
Minee L. Choi
ACAlexandre Chappard
Alexandre Chappard
BSBhanu P. Singh
Bhanu P. Singh
CMCatherine Maclachlan
Catherine Maclachlan
MRMargarida Rodrigues
Margarida Rodrigues
SGSonia Gandhi
Sonia Gandhi
Aggregation of alpha-synuclein (α-Syn) drives Parkinson’s disease (PD), although the initial stages of self-assembly and structural conversion have not been directly observed inside neurons. In this study, we tracked the intracellular conformational states of α-Syn using a single-molecule Förster resonance energy transfer (smFRET) biosensor, and we show here that α-Syn converts from a monomeric state into two distinct oligomeric states in neurons in a concentration-dependent and sequence-specific manner. Three-dimensional FRET-correlative light and electron microscopy (FRET-CLEM) revealed that intracellular seeding events occur preferentially on membrane surfaces, especially at mitochondrial membranes. The mitochondrial lipid cardiolipin triggers rapid oligomerization of A53T α-Syn, and cardiolipin is sequestered within aggregating lipid–protein complexes. Mitochondrial aggregates impair complex I activity and increase mitochondrial reactive oxygen species (ROS) generation, which accelerates the oligomerization of A53T α-Syn and causes permeabilization of mitochondrial membranes and cell death. These processes were also observed in induced pluripotent stem cell (iPSC)–derived neurons harboring A53T mutations from patients with PD. Our study highlights a mechanism of de novo α-Syn oligomerization at mitochondrial membranes and subsequent neuronal toxicity.

14 December 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
FMFabio de Moliner
Fabio de Moliner
ZKZuzanna Konieczna
Zuzanna Konieczna
LMLorena Mendive‐Tapia
Lorena Mendive‐Tapia
RSRebecca S. Saleeb
Rebecca S. Saleeb
KMKatie Morris
Katie Morris
MVMarc Vendrell
Marc Vendrell
The multiple applications of super‐resolution microscopy have prompted the need for minimally invasive labeling strategies for peptide‐guided fluorescence imaging. Many fluorescent reporters display limitations (e.g., large and charged scaffolds, non‐specific binding) as building blocks for the construction of fluorogenic peptides. Herein we have built a library of benzodiazole amino acids and systematically examined them as reporters for background‐free fluorescence microscopy. We have identified amine‐derivatized benzoselenadiazoles as scalable and photostable amino acids for the straightforward solid‐phase synthesis of fluorescent peptides. Benzodiazole amino acids retain the binding capabilities of bioactive peptides and display excellent signal‐to‐background ratios. Furthermore, we have demonstrated their application in peptide‐PAINT imaging of postsynaptic density protein‐95 nanoclusters in the synaptosomes from mouse brain tissues.

28 February 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
ACAlexandre Chappard
Alexandre Chappard
CLCraig Leighton
Craig Leighton
RSRebecca S. Saleeb
Rebecca S. Saleeb
KJKiani Jeacock
Kiani Jeacock
SBSarah R. Ball
Sarah R. Ball
MHMathew Horrocks
Mathew Horrocks
Protein misfolding and aggregation into oligomeric and fibrillar structures is a common feature of many neurogenerative disorders. Single‐molecule techniques have enabled characterization of these lowly abundant, highly heterogeneous protein aggregates, previously inaccessible using ensemble averaging techniques. However, they usually rely on the use of recombinantly‐expressed labeled protein, or on the addition of amyloid stains that are not protein‐specific. To circumvent these challenges, we have made use of a high affinity antibody labeled with orthogonal fluorophores combined with fast‐flow microfluidics and single‐molecule confocal microscopy to specifically detect α‐synuclein, the protein associated with Parkinson's disease. We used this approach to determine the number and size of α‐synuclein aggregates down to picomolar concentrations in biologically relevant samples.

19 October 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
MCMinee L. Choi
Minee L. Choi
ACAlexandre Chappard
Alexandre Chappard
BSBhanu P. Singh
Bhanu P. Singh
CMCatherine Maclachlan
Catherine Maclachlan
MRMargarida Rodrigues
Margarida Rodrigues
SGSonia Gandhi
Sonia Gandhi

2 October 2025 in Optica
Verified
Journal Article
Open access
GAGuilherme S. Arruda
Guilherme S. Arruda
KMKatie Morris
Katie Morris
AMAugusto Martins
Augusto Martins
Yue WangYue Wang
Yue Wang
SSSian Sloan-Dennison
Sian Sloan-Dennison
TKThomas F. Krauss
Thomas F. Krauss
The recent development of drugs able to mitigate neurodegenerative diseases has created an urgent need for biomarker tests that can be readily used by practitioners. Although biomarker detection directly in patients’ blood is now possible, low-cost point-of-care tests remain a challenge because relevant biomarkers, especially amyloid-β (Aβ) peptides, are small, they occur at very low concentrations, and detecting a single marker is insufficient. Here, we demonstrate a photonic resonant sensor able to detect 0.2 pg/ml of Aβ42 and Aβ40 in 1% human blood serum, equivalent to 20 pg/ml in undiluted serum, which is the clinically required level. This high performance is achieved by combining gold nanoparticle amplification with a dielectric nanopillar photonic crystal structure in a dimer configuration, while also employing an immunoassay approach for high selectivity and specificity. The design combines high resonance Q-factor, amplitude, and sensitivity, ideally suited for sensing. We also show the detection of Aβ42 and Aβ40 peptides in the same channel, which is highly relevant for assessing disease progress and opens a route toward multiplexing. Together with the handheld operation we have demonstrated previously, these photonic innovations make a major contribution to the ability to detect and monitor the progression of neurodegenerative diseases such as Alzheimer’s.

15 January 2025 in Biosensors
Verified
Journal Article
Open access
PDF file
SWStefanus Renaldi Wijaya
Stefanus Renaldi Wijaya
AMAugusto Martins
Augusto Martins
KMKatie Morris
Katie Morris
SQSteven Quinn
Steven Quinn
TKThomas F. Krauss
Thomas F. Krauss
The detection of low-molecular-weight biomarkers is essential for diagnosing and managing various diseases, including neurodegenerative conditions such as Alzheimer’s disease. A biomarker’s low molecular weight is a challenge for label-free optical modalities, as the phase change they detect is directly proportional to the mass bound on the sensor’s surface. To address this challenge, we used a resonant Young’s slit interferometer geometry and implemented several innovations, such as phase noise matching and optimisation of the fringe spacing, to maximise the signal-to-noise ratio. As a result, we achieved a limit of detection of 2.9 × 10−6 refractive index units (RIU). We validated our sensor’s low molecular weight capability by demonstrating the detection of Aβ-42, a 4.5 kDa peptide indicative of Alzheimer’s disease, and reached the clinically relevant pg/mL regime. This system builds on the guided mode resonance modality we previously showed to be compatible with handheld operation using low-cost components. We expect this development will have far-reaching applications beyond Aβ-42 and become a workhorse tool for the label-free detection of low-molecular-weight biomarkers across a range of disease types.